• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

    2/14/24 4:05:25 PM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    HARVARD BIOSCIENCE, INC.

     

    (Name of Issuer)

     

    Common Stock, $0.01 Par Value

     

    (Title of Class of Securities)

     

    416906105

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 416906105  
    (1) Names of Reporting Persons  
      Harvey Partners, LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐
      (b) ☐
       
    (3) SEC Use Only  
    (4) Citizenship or Place of Organization  
      Delaware, United States  

    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 2,557,500*  
      (6) Shared Voting Power: 0*  
      (7) Sole Dispositive Power: 2,557,500*  
      (8) Shared Dispositive Power: 0*  

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      2,557,500*
    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
      ☐
    (11) Percent of Class Represented by Amount in Row (9)
      6.0%*
    (12) Type of Reporting Person
      IA

     

    * See Item 4 for additional information.

     

     

     

     


    Item 1(a). Name Of Issuer:

     

    Harvard Bioscience, Inc. (the “Company”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    84 October Hill Road

    Holliston, Massachusetts 01746

     

    Item 2(a). Name of Person Filing:

     

    This report on Schedule 13G is being filed by Harvey Partners, LLC, a Delaware limited liability company (the “Reporting Person”).

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    120 White Plains Road

    Suite 430

    Tarrytown, NY 10591

     

    Item 2(c). Citizenship:

     

    Harvey Partners, LLC, a Delaware limited liability company.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.01 per share (the “Common Stock”).

     

    Item 2(e). CUSIP No.:

     

    416906105

     

    Item 3. If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
       
    (e) ☒ An investment adviser in accordance with § 240.13d–1(b)(1)(ii)(E);
       
    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d–1(b)(1)(ii)(F);
       
    (g) ☐ A parent holding company or control person in accordance with § 240.13d–1(b)(1)(ii)(G);
       
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
       
    (j) ☐ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       
    (k) ☐ Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ___________

     

     

     

     

    Item 4. Ownership:

     

    (a) Amount Beneficially Owned: 2,557,500*
    (b) Percent of Class: 6.0%*
    (c) Number of Shares as to which such person has:  
      (i) sole power to vote or to direct the vote: 2,557,500*
      (ii) shared power to vote or to direct the vote: 0*
      (iii) sole power to dispose or to direct the disposition of: 2,557,500*
      (iv) shared power to dispose or to direct the disposition of: 0*

     

    *Based on the information set forth in the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 7, 2023, there were 42,688,246 shares of the Company’s Common Stock outstanding as of October 31, 2023. As of December 31, 2023, Harvey SMidCap Fund, LP, a Delaware limited partnership (“SMidCap Fund”), held 339,455 shares of Common Stock and Harvey Master Fund, L.P., a Cayman Islands exempted limited partnership (“Master Fund”), held 217,388 shares of Common Stock. The Reporting Person is the investment manager of SMidCap Fund and Master Fund, and as such, possesses the sole power to vote and the sole power to direct the disposition of all securities of the Company held by SMidCap Fund and Master Fund. As of December 31, 2023, the Reporting Person held 2,000,657 shares of Common Stock in managed accounts. James A. Schwartz and Jeffrey C. Moskowitz, the Managing Members of the Reporting Person, share voting and investment power with respect to all securities beneficially owned by the Reporting Person. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person is deemed to beneficially own 2,557,500 shares of Common Stock, or 6.0% of the Common Stock deemed issued and outstanding as of December 31, 2023.

     

    As of December 31, 2023, the Reporting Person is deemed to have sole dispositive authority over 2,557,500 shares of Common Stock and sole voting authority over 2,557,500 shares of Common Stock.

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10. Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2024
         
      HARVEY PARTNERS, LLC
         
      By: /s/ Jeffrey C. Moskowitz
      Name: Jeffrey C. Moskowitz
      Title: Managing Member

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     

    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $HBIO
    Financials

    Live finance-specific insights

    See more
    • Harvard Bioscience Announces First Quarter 2025 Financial Results

      HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex

      5/12/25 7:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark

      3/12/25 7:21:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

      HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the

      6/20/23 8:01:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CFO Frost Mark T was granted 100,000 shares, increasing direct ownership by 400% to 125,000 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:52:18 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Frost Mark T claimed ownership of 25,000 shares (SEC Form 3)

      3 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:49:59 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Cote Jennifer covered exercise/tax liability with 5,687 shares, decreasing direct ownership by 3% to 159,019 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:50:40 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

      SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      5/14/25 12:28:21 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Harvard Bioscience Inc.

      10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      5/12/25 4:46:10 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      5/12/25 7:00:47 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Harvard Biosci downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight

      4/9/25 8:35:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Biosci upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously

      3/10/23 8:11:48 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KeyCorp reiterated coverage on Harvard Bioscience with a new price target

      KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously

      3/10/21 5:04:31 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harvard Bioscience Announces First Quarter 2025 Financial Results

      HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex

      5/12/25 7:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces CFO Transition

      HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Ms. Cote's resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation. Mr. Frost brings over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to the Company since January 2025. Mr. 

      4/10/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/14/24 4:02:29 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/7/24 4:02:24 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      11/14/24 12:31:23 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Harvard Bioscience Inc.

      SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      3/19/24 1:02:15 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      2/14/24 4:05:25 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials